This meta-analysis looked at how fluoxetine, an antidepressant, affects blood pressure. It combined data from several small trials involving 538 participants. The review found that fluoxetine was linked to a small but statistically significant increase in both systolic and diastolic blood pressure compared to a placebo. The average rise was about 7.5 mmHg for systolic and 4.2 mmHg for diastolic pressure. A subgroup analysis suggested the increase might be larger with longer treatment duration. Safety data, such as adverse events or discontinuations, were not reported in the included studies. The main reason to be careful is that the evidence comes from a limited number of studies with substantial differences between them, which makes the findings uncertain. Readers should know this is an early signal from a small body of research. It does not prove fluoxetine causes high blood pressure, and it should not change anyone's treatment without a doctor's guidance.
Fluoxetine Linked to Small but Significant Blood Pressure RiseFluoxetine linked to small rise in blood pressure
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Fluoxetine may cause small but significant increases in blood pressure; monitor patients accordingly.
A meta-analysis of randomized controlled trials investigated the effect of fluoxetine on blood pressure in 538 participants. The analysis revealed that fluoxetine was associated with statistically significant increases in both systolic and diastolic blood pressure compared to placebo.
The weighted mean difference for systolic blood pressure was 7.47 mmHg (95% CI: 0.14 to 14.80; p = 0.046), and for diastolic blood pressure, it was 4.19 mmHg (95% CI: 0.44 to 7.93; p = 0.028). Subgroup analysis based on treatment duration showed even larger increases: 10.66 mmHg for systolic and 6.65 mmHg for diastolic.
These findings should be interpreted cautiously due to substantial heterogeneity and the limited number of included studies. The clinical relevance of these blood pressure changes may be modest but warrants monitoring in patients prescribed fluoxetine, especially those with cardiovascular risk factors.
Further research is needed to confirm these results and explore potential mechanisms. Clinicians should consider periodic blood pressure checks in patients on fluoxetine therapy.
What this means for you:
A review suggests fluoxetine may slightly raise blood pressure, but the evidence is limited and uncertain. 
View Original Abstract ↓
Background and aimThere are ongoing controversies regarding the impact of fluoxetine on blood pressure (BP), and a comprehensive analysis specifically addressing this relationship is lacking. Given the limited detail in existing literature on BP fluctuations during fluoxetine treatment, we conducted this meta-analysis to evaluate BP variations, providing clinically relevant insights.MethodsA structured and comprehensive review was conducted using systematic review and meta-analytic approaches. Only randomized controlled trials (RCTs) comparing fluoxetine with placebo were included. Exhaustive searches were performed across major scholarly databases, including Scopus, Web of Science, Embase, and PubMed/MEDLINE, covering all records up to July 28, 2025. Pooled estimates were calculated using the DerSimonian and Laird random-effects model, and results were reported as weighted mean differences (WMDs) with corresponding 95% confidence intervals (CIs).ResultsFive RCT arms encompassing a total of 538 participants were included in the current meta-analysis. Fluoxetine treatment was associated with a statistically significant increase in systolic BP (SBP) (WMD: 7.47 mmHg; 95% CI: 0.14 to 14.80; p = 0.046) and diastolic BP (DBP) (WMD: 4.19 mmHg; 95% CI: 0.44 to 7.93; p = 0.028); however, these findings should be interpreted cautiously due to substantial heterogeneity and the limited number of included studies. Subgroup analyses based on treatment duration indicated that increases in SBP (WMD: 10.66 mmHg; 95% CI: 1.53 to 19.80; p = 0.022) and DBP (WMD: 6.65 mmHg; 95% CI: 4.30 to 8.99; p
Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk
People with lupus face higher heart disease risk but genetics show no direct link
Related in Cardiology
Higher Triglyceride-glucose index levels are associated with increased risk of Atrial Fibrillation
Higher Triglyceride-Glucose Index Linked to Increased Risk of Atrial Fibrillation
This meta-analysis of 25,376 individuals found significantly higher TyG index levels in patients with Atrial Fibrillation compared to those …
A high triglyceride-glucose index may serve as a potential marker for identifying people at risk for atrial fibrillation and related heart c…
Supraventricular tachyarrhythmias occur more frequently in patients with Arrhythmogenic Cardiomyopathy and Brugada Syndrome
Heart conditions like Brugada syndrome increase risk of rapid heartbeats
This systematic review of 30 studies indicates that supraventricular tachyarrhythmias (SVT) are more frequent in patients with Arrhythmogeni…
Patients with certain heart conditions face a higher risk of fast heartbeats, which can lead to complications like heart failure or unnecess…
Higher serum total bilirubin levels associated with lower long-term risk in coronary heart disease patients
High bilirubin levels linked to lower heart risk in some cases
This meta-analysis examined the association between serum total bilirubin and major adverse cardiovascular events in patients undergoing per…
New data suggests high bilirubin might protect patients with coronary heart disease from long-term risks, though the evidence is still early…
Gut microbiota-derived aromatic amino acid metabolites influence myocardial injury and risk of major adverse cardiac events
Gut Microbiota Metabolites Linked to Cardiovascular Disease Risk
This systematic review synthesizes the roles of gut microbiota-derived aromatic amino acid (AAA) metabolites in cardiovascular disease. The …
Specific compounds from gut bacteria, like Phenylacetylglutamine, are linked to heart damage and increased risks for cardiovascular disease.
From Other Specialties
Bortezomib, cyclophosphamide, and dexamethasone achieved remission in a patient with AL amyloidosis and POEMS syndrome
Treatment shows success for heart failure and rare blood diseases
This case report and literature review describes the treatment of an elderly male with concurrent AL amyloidosis and POEMS syndrome. The pat…
A new look at a complex case reveals how a specific drug combination helped an elderly man with multiple rare conditions.
Current molecular and cellular phenotypes do not yet support clinical subtype identification for recurrent pregnancy loss
New research looks at why some pregnancies end early
This mini review examines maternal-fetal interface abnormalities in patients with unexplained recurrent pregnancy loss (URPL). The authors c…
Doctors are looking for better ways to understand and treat the reasons behind repeated pregnancy loss.
TNF inhibitors may be effective for juvenile idiopathic arthritis in patients with DiGeorge syndrome
Biologic treatments show promise for children with DiGeorge syndrome
This case report and literature review examines the management of juvenile idiopathic arthritis (JIA) in children with DiGeorge syndrome (DG…
Children with both DiGeorge syndrome and juvenile idiopathic arthritis may find relief from joint pain using specific biologic medications.
mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTs
Mobile Health Apps Help Manage Blood Sugar in Type 2 Diabetes
This meta-analysis of 19 RCTs with 2,166 participants found that mobile health (mHealth) app interventions significantly reduced HbA1c (MD -…
Using mobile health applications can help people with type 2 diabetes lower their blood sugar levels and improve their overall quality of li…